{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:41:48Z","timestamp":1791510108528,"version":"4.3.4"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Use of genetically engineered rodents is often considered a valuable exercise to assess potential safety concerns associated with the inhibition of a target pathway. When there are potential immunomodulatory risks associated with the target, these genetically modified animals are often challenged with various pathogens in an acute setting to determine the risk to humans. However, the applicability of the results from infection models is seldom assessed when significant retrospective human data become available. Thus, the purpose of the current review is to compare the outcomes of infectious pathogen challenge in mice with genetic deficiencies in TNF-\u03b1, IL17, IL23, or Janus kinase pathways with infectious outcomes caused by inhibitors of these pathways in humans. In general, mouse infection challenge models had modest utility for hazard identification and were generally only able to predict overall trends in infection risk. These models did not demonstrate significant value in evaluating specific types of pathogens that are either prevalent (ie rhinoviruses) or of significant concern (ie herpes zoster). Similarly, outcomes in mouse models tended to overestimate the severity of infection risk in human patients. Thus, there is an emerging need for more human-relevant models that have better predictive value. Large meta-analyses of multiple clinical trials or post-marketing evaluations remains the gold-standard for characterizing the true infection risk to patients.<\/jats:p>","DOI":"10.1093\/toxsci\/kfz116","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T19:26:50Z","timestamp":1557343610000},"page":"260-272","source":"Crossref","is-referenced-by-count":5,"title":["Predicting Human Infection Risk: Do Rodent Host Resistance Models Add Value?"],"prefix":"10.1093","volume":"170","author":[{"given":"Kai Connie","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Safety Assessment, Genentech, Inc., South San Francisco, California 94080"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Safety Assessment, Genentech, Inc., South San Francisco, California 94080"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Safety Assessment, Genentech, Inc., South San Francisco, California 94080"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"2019072509002329600_kfz116-B1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc. Patient Saf"},{"key":"2019072509002329600_kfz116-B2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nm1713","article-title":"Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation","volume":"14","author":"Bartlett","year":"2008","journal-title":"Nat. Med"},{"key":"2019072509002329600_kfz116-B4","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","article-title":"Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin","volume":"162","author":"Bean","year":"1999","journal-title":"J. Immunol."},{"key":"2019072509002329600_kfz116-B5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0300985817747330","article-title":"Systemic loss of C-terminal Src kinase expression elicits spontaneous suppurative inflammation in conditional knockout mice","volume":"55","author":"Berman-Booty","year":"2018","journal-title":"Vet. Pathol."},{"key":"2019072509002329600_kfz116-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"2019072509002329600_kfz116-B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrg1019","article-title":"Mice, microbes and models of infection","volume":"4","author":"Buer","year":"2003","journal-title":"Nat. Rev. Genet"},{"key":"2019072509002329600_kfz116-B9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.smim.2017.12.008","article-title":"Human genetics of infectious diseases: Unique insights into immunological redundancy","volume":"36","author":"Casanova","year":"2018","journal-title":"Semin. Immunol."},{"key":"2019072509002329600_kfz116-B11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"2019072509002329600_kfz116-B12","doi-asserted-by":"crossref","first-page":"6779.","DOI":"10.1038\/s41598-017-07261-1","article-title":"A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep"},{"key":"2019072509002329600_kfz116-B13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1172\/JCI40891","article-title":"IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice","volume":"120","author":"Cho","year":"2010","journal-title":"J. Clin. Invest"},{"key":"2019072509002329600_kfz116-B14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"2019072509002329600_kfz116-B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J. Exp. Med"},{"key":"2019072509002329600_kfz116-B16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.168.3.1322","article-title":"Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present","volume":"168","author":"Cooper","year":"2002","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B17","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.4049\/jimmunol.0900995","article-title":"Critical role of IL-17RA in immunopathology of influenza infection","volume":"183","author":"Crowe","year":"2009","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B18","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.ajpath.2011.09.003","article-title":"Negative regulation of lung inflammation and immunopathology by TNF-alpha during acute influenza infection","volume":"179","author":"Damjanovic","year":"2011","journal-title":"Am. J. Pathol."},{"key":"2019072509002329600_kfz116-B19","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.4049\/jimmunol.1302729","article-title":"Soluble, but not transmembrane, TNF-alpha is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology","volume":"192","author":"DeBerge","year":"2014","journal-title":"J. Immunol."},{"key":"2019072509002329600_kfz116-B20","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/IAI.67.7.3571-3579.1999","article-title":"Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium","volume":"67","author":"Ehlers","year":"1999","journal-title":"Infect. Immun."},{"key":"2019072509002329600_kfz116-B21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cimid.2016.08.006","article-title":"Humanized mice in infectious diseases","volume":"49","author":"Ernst","year":"2016","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"2019072509002329600_kfz116-B22","author":"European Medicines Agency","year":"2009"},{"key":"2019072509002329600_kfz116-B23","author":"European Medicines Agency","year":"2015"},{"key":"2019072509002329600_kfz116-B24","author":"European Medicines Agency","year":"2016"},{"key":"2019072509002329600_kfz116-B25","author":"European Medicines Agency","year":"2017"},{"key":"2019072509002329600_kfz116-B26","author":"European Medicines Agency","year":"2018"},{"key":"2019072509002329600_kfz116-B27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmun. Rev"},{"key":"2019072509002329600_kfz116-B28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/imm.12130","article-title":"Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection","volume":"140","author":"Freches","year":"2013","journal-title":"Immunology"},{"key":"2019072509002329600_kfz116-B30","first-page":"95","article-title":"Varicella-zoster virus infection: Natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol"},{"key":"2019072509002329600_kfz116-B31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/IAI.00933-08","article-title":"Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestine","volume":"77","author":"Godinez","year":"2009","journal-title":"Infect. Immun"},{"key":"2019072509002329600_kfz116-B33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/ijd.IJD_233_16","article-title":"Secukinumab\u2014First in class interleukin-17A inhibitor for the treatment of psoriasis","volume":"62","author":"Godse","year":"2017","journal-title":"Indian J. Dermatol"},{"key":"2019072509002329600_kfz116-B34","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1128\/IAI.69.11.6651-6659.2001","article-title":"Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis","volume":"69","author":"Goncalves","year":"2001","journal-title":"Infect. Immun"},{"key":"2019072509002329600_kfz116-B35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J. Invest. Dermatol"},{"key":"2019072509002329600_kfz116-B38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"Br. J. Dermatol"},{"key":"2019072509002329600_kfz116-B39","author":"Green","year":"1998"},{"key":"2019072509002329600_kfz116-B40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1086\/653738","article-title":"Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice","volume":"202","author":"Guiton","year":"2010","journal-title":"J. Infect. Dis"},{"key":"2019072509002329600_kfz116-B42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/pathogens2020364","article-title":"Animal models of varicella zoster virus infection","volume":"2","author":"Haberthur","year":"2013","journal-title":"Pathogens"},{"key":"2019072509002329600_kfz116-B43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.20050193","article-title":"Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae","volume":"202","author":"Happel","year":"2005","journal-title":"J. Exp. Med"},{"key":"2019072509002329600_kfz116-B44","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2014An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol"},{"key":"2019072509002329600_kfz116-B45","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J. Infect. Dis"},{"key":"2019072509002329600_kfz116-B46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"J. Dermatol"},{"key":"2019072509002329600_kfz116-B47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"2019072509002329600_kfz116-B48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"2019072509002329600_kfz116-B49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/IAI.73.1.617-621.2005","article-title":"Interleukin-17\/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection","volume":"73","author":"Kelly","year":"2005","journal-title":"Infect. Immun"},{"key":"2019072509002329600_kfz116-B50","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4081\/reumatismo.2011.155","article-title":"GISEA: An Italian biological agents registry in rheumatology","volume":"63","author":"Lapadula","year":"2011","journal-title":"Reumatismo"},{"key":"2019072509002329600_kfz116-B55","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B56","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B57","author":"Leshin","year":"2011"},{"key":"2019072509002329600_kfz116-B58","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.173.3.1887","article-title":"IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12","volume":"173","author":"Lieberman","year":"2004","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1526-0542(03)00031-9","article-title":"The classification of viruses infecting the respiratory tract","volume":"4","author":"Mackie","year":"2003","journal-title":"Paediatr. Respir. Rev"},{"key":"2019072509002329600_kfz116-B60","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J. Infect. Dis"},{"key":"2019072509002329600_kfz116-B61","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(01)00184-4","article-title":"Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria","volume":"15","author":"Malaviya","year":"2001","journal-title":"Immunity"},{"key":"2019072509002329600_kfz116-B63","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1073\/pnas.94.15.8093","article-title":"Characterization of tumor necrosis factor-deficient mice","volume":"94","author":"Marino","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"2019072509002329600_kfz116-B64","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.4049\/jimmunol.0901588","article-title":"IL-23 is required for protection against systemic infection with Listeria monocytogenes","volume":"183","author":"Meeks","year":"2009","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B65","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/ced.12390","article-title":"Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis","volume":"39","author":"Meng","year":"2014","journal-title":"Clin. Exp. Dermatol"},{"key":"2019072509002329600_kfz116-B93","author":"Meroni","year":"2014"},{"key":"2019072509002329600_kfz116-B66","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B67","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1086\/430126","article-title":"Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: Tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha","volume":"41","author":"Moore","year":"2005","journal-title":"Clin. Infect. Dis"},{"key":"2019072509002329600_kfz116-B68","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00399-17","article-title":"Interleukin-17A-deficient mice are highly susceptible to Toxoplasma gondii infection due to excessively induced T. gondii HSP70 and interferon gamma production","volume":"85","author":"Moroda","year":"2017","journal-title":"Infect. Immun."},{"key":"2019072509002329600_kfz116-B69","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B70","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol"},{"key":"2019072509002329600_kfz116-B71","author":"Peretz","year":"2016"},{"key":"2019072509002329600_kfz116-B72","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4049\/jimmunol.160.2.943","article-title":"TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation","volume":"160","author":"Peschon","year":"1998","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B73","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol"},{"key":"2019072509002329600_kfz116-B74","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2019072509002329600_kfz116-B75","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br. J. Dermatol"},{"key":"2019072509002329600_kfz116-B76","first-page":"290","article-title":"Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN","volume":"60","author":"Sarzi-Puttini","year":"2008","journal-title":"Reumatismo"},{"key":"2019072509002329600_kfz116-B77","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.4049\/jimmunol.170.12.6172","article-title":"Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gondii in the central nervous system","volume":"170","author":"Schluter","year":"2003","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov"},{"key":"2019072509002329600_kfz116-B94","author":"Shanti"},{"key":"2019072509002329600_kfz116-B79","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun. Rev"},{"key":"2019072509002329600_kfz116-B80","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B81","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2019072509002329600_kfz116-B82","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B83","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn's disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"key":"2019072509002329600_kfz116-B84","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/ard.2005.043299","article-title":"Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study","volume":"65","author":"van Riel","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"2019072509002329600_kfz116-B85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2019072509002329600_kfz116-B86","author":"Weir","year":"1997"},{"key":"2019072509002329600_kfz116-B87","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2019072509002329600_kfz116-B88","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019072509002329600_kfz116-B89","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.4049\/jimmunol.1001763","article-title":"IL-17A-producing gammadeltaT cells promote CTL responses against Listeria monocytogenes infection by enhancing dendritic cell cross-presentation","volume":"185","author":"Xu","year":"2010","journal-title":"J. Immunol"},{"key":"2019072509002329600_kfz116-B90","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med"},{"key":"2019072509002329600_kfz116-B91","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: A systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J. Invest. Dermatol"},{"key":"2019072509002329600_kfz116-B92","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrd987","article-title":"Knockouts model the 100 best-selling drugs\u2014Will they model the next 100?","volume":"2","author":"Zambrowicz","year":"2003","journal-title":"Nat. Rev. Drug Discov"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfz116\/28823236\/kfz116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/toxsci\/article-pdf\/170\/2\/260\/28999050\/kfz116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T10:47:21Z","timestamp":1694861241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/170\/2\/260\/5491836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,5,20]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfz116","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,20]]}}}